Destiny Pharma PLC. Stock Analysis DEST.L

Destiny Pharma Plc operates as a clinical biotechnology company, which engages in the discovery, development and commercialization of new antimicrobial products. The company is headquartered in Brighton, Sussex and currently employs 19 full-time employees. The firm is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The firm's drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA), and has the potential to reduce hospitalization stay, accelerate recovery and rehabilitation and improve quality of life for patients undergoing vital surgeries. The Company’s earlier stage pipeline is focused on other indications including two, separate dermal programs incorporating its XF platform.